Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Insmed Inc (INSM) Com Stock USD 0.01

Sell:$35.75 Buy:$36.00 Change: $1.39 (3.74%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Sell:$35.75
Buy:$36.00
Change: $1.39 (3.74%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Sell:$35.75
Buy:$36.00
Change: $1.39 (3.74%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Contact details

Address:
700 US Highway 202/206
BRIDGEWATER
08807-1704
United States
Telephone:
+1 (908) 9779900
Website:
www.insmed.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
INSM
ISIN:
US4576693075
Market cap:
$4.08 billion
Shares in issue:
101.87 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • William Lewis
    Chairman of the Board, President, Chief Executive Officer
  • Sara Bonstein
    Chief Financial Officer
  • Roger Adsett
    Chief Operating Officer
  • John Goll
    Chief Accounting Officer
  • John Soriano
    Chief Compliance Officer
  • Martina Flammer
    Chief Medical Officer
  • Christine Pellizzari
    Chief Legal Officer
  • S. Nicole Schaeffer
    Chief People Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.